

NOVO NORDISK A S  
Form 6-K  
February 10, 2014

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

**February 10, 2014**

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé  
DK- 2880, Bagsvaerd  
Denmark**

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_

**Trading in Novo Nordisk shares by board members, executives and associated persons on 7 February 2014.**

**Bagsværd, Denmark, 10 February 2014** In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk

Below reflects the stock split of the Novo Nordisk B shares and ADRs which was implemented in January 2014. Following the five-for-one ratio split, Novo Nordisk's B shares are calculated in units of DKK 0.2. The ratio of Novo Nordisk's B shares to ADRs remains 1:1.

Please find below a statement of trading in shares issued by Novo Nordisk.

|   |   |
|---|---|
| <b>Name</b>                             | <b>Anne Marie Kverneland</b>            |
| <b>Reason for reporting</b>             | <b>Member of the Board of Directors</b> |
| <b>Financial instrument and ID code</b> | <b>Novo Nordisk B DK0060534915</b>      |
| <b>Type of transaction</b>              | <b>Sale of shares</b>                   |
| <b>Date of transaction</b>              | <b>7 February 2014</b>                  |
| <b>Place of transaction</b>             | <b>NASDAQ OMX Copenhagen</b>            |
| <b>Volume of transaction</b>            | <b>636 shares</b>                       |
| <b>Total value of transaction</b>       | <b>DKK 145,835</b>                      |

**Novo Nordisk A/S** Novo Allé Telephone: Internet:  
Investor Relations 2880 +45 4444 8888 www.novonordisk.com  
Bagsværd  
Denmark CVR no:  
24 25 67 90

Company announcement No 07/ 2014

**Definitions and background information:**

**Publication**

Publication shall take place no later than two working days after the trading by board members or executives or notification of trading by associated persons. Publication is only required when the total amount of transactions of a specific board member/executive and his/her associated persons in any one calendar year has reached 5,000 euros.

**Who are board members, executives and associated persons?**

Board members and executives are members of the Board of Directors and Executive Management, respectively, of Novo Nordisk A/S. Associated persons are defined as the following persons associated to a board member/executive: 1) spouse or cohabitant, 2) children under the age of 18 years, 3) relatives defined as brothers, sisters, parents, grandparents etc, children, grandchildren etc who have shared the same household with a board member/executive for at least one year, and 4) any legal person, including a company, a foundation or a partnership, which is controlled directly or indirectly by a board member/executive and/or a person mentioned in 1)–3), or to which a board member/executive and/or a person mentioned in 1)–3) has managerial responsibilities or economic interests substantially equivalent to the legal person.

**What is trading/transaction?**

Trading is any kind of transaction, including shares purchased or otherwise acquired, shares sold or otherwise disposed, gifts, mortgages and grants and exercise of options, but not heritage.

**What is financial instrument and ID code?**

Financial instrument includes shares listed on the NASDAQ OMX Copenhagen and ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US-based employees. The ID code is the code (ISIN DK0060534915) of the Novo Nordisk share on the NASDAQ OMX Copenhagen or the code (NVO) on New York Stock Exchange.

**What is date and place of transaction?**

Date of transaction is the actual transaction date. The place of transaction is the actual place of transaction, ie NASDAQ OMX Copenhagen or New York Stock Exchange.

**What is volume and value of transaction?**

The volume of transaction is the number of shares (of DKK 0.20 nominal value) or other financial instruments traded. The transaction value is the number of shares traded multiplied by the transaction price. The exchange rate of the Danish Central Bank (Nationalbanken) on the date of transaction is used for calculating the transaction value in DKK in case of ADRs listed on New York Stock Exchange.

**Novo Nordisk A/S** Novo Allé Telephone: Internet:  
Investor Relations 2880 +45 4444 8888 www.novonordisk.com  
Bagsværd  
Denmark CVR no:  
24 25 67 90

Company announcement No 07 / 2014

Page 3 of 3

*Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 38,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com).*

**Further information**

*Media:*

Anne Margrethe Hauge +45 4442 3450 [amhg@novonordisk.com](mailto:amhg@novonordisk.com)  
Ken Inchausti (US) +1 609 514 8316 [kiau@novonordisk.com](mailto:kiau@novonordisk.com)

*Investors:*

Kasper Roseeuw Poulsen +45 3079 4303 [krop@novonordisk.com](mailto:krop@novonordisk.com)  
Frank Daniel Mersebach +45 3079 0604 [fdni@novonordisk.com](mailto:fdni@novonordisk.com)  
Lars Borup Jacobsen +45 3075 3479 [lbpj@novonordisk.com](mailto:lbpj@novonordisk.com)  
Daniel Bohsen +45 3079 6376 [dabo@novonordisk.com](mailto:dabo@novonordisk.com)  
Jannick Lindegaard (US) +1 609 235 8567 [jlis@novonordisk.com](mailto:jlis@novonordisk.com)

**Novo Nordisk A/S** Novo Allé Telephone: Internet:  
Investor Relations 2880 +45 4444 8888 [www.novonordisk.com](http://www.novonordisk.com)  
Bagsværd  
Denmark CVR no:  
24 25 67 90

Company announcement No 07 / 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: February 10, 2014 Lars Rebien Sørensen,

President and Chief Executive Officer